Doxylamine
| Doxylamine | |
|---|---|
| Salts [] | |
|---|---|
| Doxylamine succinate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 270.37 g/mol [1] |
| Appearance | LIQ [1] |
| Melting point | < 25 °C [1] |
| Boiling point | 279 to 286 °F at 0.5 mmHg (NTP, 1992) [1] |
| Solubility | 1 g/ml (succinate salt) [1] |
| Predicted LogP | 2.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H22N2O |
| IUPAC name | N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine |
| SMILES | CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C |
| InChI | InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3 |
| InChIKey | HCFDWZZGGLSKEP-UHFFFAOYSA-N |
| CAS number | 469-21-6 |
| UNII | 95QB77JKPL |
| PubChem CID | 3162 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 10–12 hours (range 7–15 hours) |
| Metabolism | Hepatic (CYP2D6, CYP1A2, CYP2C9) |
| Excretion | Urine (60%), feces (40%)[3] |
| Routes of administration | By mouth |
Doxylamine (also known as Dossilamina, Doxylaminum, Doxilminio, doxilamina, 2-Dimethylaminoethoxyphenylmethyl-2-picoline, N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine, Phenyl-2-pyridylmethyl-β-N,N-dimethylaminoethyl ether, 2-(α-(2-(Dimethylamino)ethoxy)-α-methylbenzyl)pyridine, dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine or Ethanamine, N,N-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-) is a substance of the phenylethanolamine class.
Chemistry
Salts []
Doxylamine is typically found in the form of its succinate salt.
Stereochemistry []
Doxylamine is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Doxylamine matches Lipinski's rule of five.Pharmacology
ATC Classification
- respiratory system (R)
- antihistamines for systemic use (R06)
- antihistamines for systemic use (R06A)
- aminoalkyl ethers (R06AA)
- doxylamine (R06AA09)
MeSH Classification
Mechanism of action []
Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. [1]
Interactions []
Subjective effects []
| 0xea / Doxylamine [] | |
|---|---|
Routes:
| |
| emily / Doxylamine [] | |
|---|---|
Routes:
| |
| nervewing / Doxylamine [] | |
|---|---|
| Pilz / Doxylamine [] | |
|---|---|
Routes:
| |
Experience reports
Legal status []
- Australia: Doxylamine is a Schedule 3.
- United States: Doxylamine is a OTC.
- Other: Doxylamine is a SE: Rx-only.[4]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3162, Doxylamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3162
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Doxylamine. UNII: 95QB77JKPL. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/95QB77JKPL
New Zealand Datasheet: Doxylamine Succinate. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. 16 July 2008. http://www.medsafe.govt.nz/profs/datasheet/d/Dozilecap.pd
Bonjesta, Tablett med modifierad frisättning 20 mg/20 mg. Fass.se. https://fass.se/health/product/20210825000039/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 11:32:53 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 11:32:48 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 11:32:48 |
| gsrs | ok | 2026-11-20 11:32:50 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0001936) | 2026-11-20 11:32:48 |
| kegg | ok | 2026-11-20 11:32:51 |
| pubchem | ok | 2026-11-20 11:32:47 |
| ok | 2026-11-20 11:32:48 | |
| sider | missing (not in SIDER) | 2026-11-20 11:32:48 |
| structure | ok | 2026-11-20 11:32:48 |
| wikipedia | ok | 2026-11-20 11:32:49 |